Education Intervention for Lung Cancer Screening Compliance
(QLC+ Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if educational materials can help individuals with untreated COPD (a lung condition that makes breathing difficult) or cardiovascular disease (heart-related issues) adhere to their medication plans more effectively over a year. Participants will be divided into groups based on whether they have COPD or cardiovascular disease. Eligible participants have been screened for lung cancer and either have untreated COPD or specific heart concerns identified through a CT scan. This trial suits those diagnosed with COPD who are not currently on the recommended treatment or those with a heart condition identified through lung cancer screening. As an unphased trial, it offers a unique opportunity to contribute to understanding how educational support can improve medication adherence.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it seems to focus on people who are not on certain recommended therapies, so you might not need to stop any current treatments.
What prior data suggests that this educational intervention is safe for patients with COPD and cardiovascular disease?
Research has shown that educational programs, like those in this trial, are generally safe. Studies have found that these programs help people manage chronic diseases such as COPD (a lung condition) and CVD (heart disease) without causing harm. Participants in past studies did not report any serious side effects from receiving educational materials and treatment advice.
Additionally, self-management programs, which often include educational components, have demonstrated positive results. These programs help people better manage their conditions, leading to fewer hospital visits. This suggests that the educational approach is safe and well-received by participants.
In this trial, the educational programs aim to assist patients and their healthcare providers in better managing conditions that often occur with lung cancer. While specific side effects or risks are not detailed, past experiences with similar programs support their safety and benefits.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores how educational interventions can boost compliance with lung cancer screening recommendations. Unlike traditional approaches that might focus solely on medical interventions, this trial emphasizes the power of informed decision-making by providing tailored educational materials and treatment recommendations to patients, general practitioners, and pharmacists. The unique aspect of this method is its holistic approach, aiming to bridge knowledge gaps and promote collaborative healthcare. By enhancing understanding and communication among all parties, this trial could lead to more proactive and effective lung cancer screenings, potentially catching conditions earlier and improving outcomes.
What evidence suggests that this educational intervention is effective for improving medication adherence in COPD and cardiovascular disease patients?
Research has shown that educational programs can help people better adhere to treatment plans for diseases like COPD (a lung disease) and CVD (heart disease). Studies have found that well-trained and informed healthcare providers can enhance their knowledge and practices, leading to improved patient health. Specifically, one study discovered that these educational efforts increased understanding of the disease and treatment adherence within just one year. Patients may be more likely to take their medications as prescribed when both they and their doctors are well-informed. In this trial, some participants will receive educational materials as part of the intervention arms for COPD and CVD. Additionally, incorporating these educational materials into existing programs, like lung cancer screenings, can amplify these benefits.12346
Are You a Good Fit for This Trial?
This trial is for individuals who have been screened for lung cancer and found to have mild to severe coronary artery calcification (CAC) without being on recommended lipid-lowering therapy, or diagnosed with symptomatic COPD not treated with first-line therapies. It's not suitable for those already on appropriate COPD treatment, without CAC, with known heart issues, diabetes, or a high suspicion of lung cancer.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Educational intervention for untreated COPD and cardiovascular disease integrated in an existing lung cancer screening program
Follow-up
Participants are monitored for safety and effectiveness after intervention
What Are the Treatments Tested in This Trial?
Interventions
- Educational material and treatment recommendations for patients, general practitioners and pharmacists
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nicole Ezer, MD, FRCPC, MPH
Lead Sponsor